Testing XER-001 with radiation for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new way to deliver a drug called amifostine (XER-001) alongside intense radiation therapy (SBRT) for people with locally advanced pancreatic cancer that can't be surgically removed. The goal is to see if it's safe and effective at protecting healthy tissue while targeting the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of pancreatic cancer called adenocarcinoma
- Your cancer is locally advanced or cannot be removed by surgery
- You have completed at least one round of chemotherapy (like FOLFIRINOX or gemcitabine/Abraxane)
- Your cancer has not spread to other organs (like the liver or lungs)
- Your tumor does not grow into the stomach or intestines
- You are 18 or older and in reasonably good health (able to care for yourself)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining targeted radiation with an at-home “tumor treating fields” device can better control locally advanced pancreatic cancer. It may help by attacking cancer cells in more than one way after prior chemotherapy.
This trial tests a special, high-dose radiation treatment for pancreatic cancer that has not spread but cannot be removed with surgery. The goal is to shrink the tumor and improve control of the cancer in the abdomen.
This study tests an investigational drug (RR001) given after chemotherapy for people with locally advanced pancreatic cancer that hasn't spread. It aims to see if the new treatment is safe and may help shrink tumors that can be reached with a needle injection.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
This study tests a new approach for locally advanced pancreatic cancer that hasn't spread. It combines precise high-dose radiation with an experimental immunotherapy (PCX12) injected directly into the tumor to see if it's safe and tolerable.
This trial tests a new treatment that uses tiny alpha radiation sources placed directly into the tumor to destroy cancer cells. It is for people with pancreatic cancer that has not spread but cannot be removed surgically, and who have already tried at least one type of chemotherapy or cannot take more chemo.
Hear when a new Locally Advanced Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.